Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00495469
First received: June 29, 2007
Last updated: February 21, 2013
Last verified: February 2013
  Purpose

This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of GSK189075 (an SGLT2 inhibitor) compared to placebo, administered over 12 weeks in treatment-naive subjects with type 2 diabetes mellitus


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: GSK189075
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Hemoglobin A1c (HbA1c) at Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in FPG, fructosamine, and lipids from baseline to week 12 Evaluation of adverse events/safety and tolerability Change in vital signs and weight [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Secondary efficacy endpoints include change from baseline in HbA1c over time; change from baseline in FPG, fructosamine, and lipids; proportion of HbA1c and FPG responders; change from baseline in body weight [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
  • Safety endpoints include AEs, incidence of hypoglycemia, vital signs, ECGs and standard laboratory tests. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 252
Study Start Date: August 2007
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
GSK189075
Drug: GSK189075
12 weeks experimental drug
Other Name: GSK189075
Placebo Comparator: Arm 2
Placebo
Drug: GSK189075
12 weeks experimental drug
Other Name: GSK189075

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with a documented diagnosis of T2DM and HbA1c ≥7.0% and ≤9.5% measured by the central laboratory at Visit 1.

    • Note: Subjects with HbA1c <7.5% must have a fasting fingerstick glucose ≥7 mmol/L (126 mg/dL) at Week 0, prior to randomization.
    • Note: The proportion of subjects who are randomized with an HbA1c <7.5% will be limited to be no more than 20% (approximately 51 subjects)
  • Subjects who are treatment-naïve, and have not taken insulin, or any oral or injectable anti-diabetic medication in the past 3 months and have not taken a glucose lowering agent for ≥4 weeks at any time in the past, or subjects who are newly diagnosed and treated with diet and exercise for a minimum of 6 weeks
  • Subjects who are 18 to 70 years of age inclusive at the time of Screening.
  • Females of childbearing and non-childbearing and potential are eligible to participate as follows:

    • Women of childbearing potential must be willing to use one of the following contraception methods: intrauterine device, condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent for at least 30 days prior to the start of study medication, throughout the study and the follow-up visit. Note: use of oral contraceptives is not permitted.
    • Women of non-child bearing potential are defined as follows: females regardless of age, with functioning ovaries who have a current documented tubal ligation, or who are surgically sterile (i.e. documented total hysterectomy or bilateral oophorectomy), or females who are post-menopausal.

All females must have a negative urine pregnancy test on the day of, and prior to randomization.

  • Informed Consent: a signed and dated written consent must be obtained from the subject before any procedures are performed.

Exclusion Criteria:

  • Metabolic Disease

    • Diagnosis of Type 1 diabetes mellitus
    • History of ketoacidosis which has required hospitalization
    • Thyroid disorder
    • TSH <0.4 MIU/L (<0.4 MCIU/mL) or >5.5 mIU/L (>5.5 MCIU/mL) at Screening
    • BMI of <22 kg/m2 or >43 kg/m2
    • Significant weight gain or loss (as defined as >5% of total body weight) in the 3 months prior to Screening
  • Diabetic Medication

    • Has taken insulin, or any oral or injectable anti-diabetic medication within 3 months of screening
    • Has taken insulin or any oral or injectable anti-diabetic medication ≥4 weeks at any time in the past
  • Cardiovascular Disease

Recent history or presence of clinically significant acute cardiovascular disease including:

  • Documented myocardial infarction in the 6 months prior to Screening.
  • Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery either planned and/or occurred in the 6 months prior to Screening.
  • Unstable angina in the 6 months prior to Screening.
  • Clinically significant supraventricular arrhythmias requiring medical therapy, or history of nonsustained or sustained ventricular tachycardia. Symptomatic valvular heart disease or valvular heart disease requiring therapy other than endocarditis prophylaxis.
  • Congestive heart failure (CHF, New York Heart Association (NYHA) Class II to IV) requiring pharmacologic treatment or the NYHA Class criteria in accordance with the local prescribing information for pioglitazone.
  • Blood pressure (BP) >150/100mmHg. If a subject is receiving permitted antihypertensive therapy, then they must be on stable dose(s) of therapy for at least 4 weeks prior to Screening.
  • Based on local readings, the subject has an initial QTc interval (Bazett's)≥450msec at Screening, and after two additional ECGs taken 5 minutes apart, the average of the QTC interval from the three ECGs is ≥450msec.
  • Other clinically significant ECG abnormalities which, in the opinion of the Investigator, may affect the interpretation of efficacy or safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.
  • Fasting triglycerides ≥400mg/dL (4.56mmol/L) at Screening. If a subject is receiving permitted lipid-lowering therapy, then they must be on a stable dose(s) of therapy for at least 6 weeks prior to Screening. Niacin and bile acid sequestrants are prohibited.

    • Hepatic Disease

Has a diagnosis of active hepatitis (hepatitis B surface antigen or hepatitis C antibody), or clinically significant hepatic enzyme elevation including:

Any one of the following enzymes greater than 2 times the upper limit of the reference range (ULRR) value at Screening.

  • alanine aminotransferase (ALT)
  • aspartate aminotransferase (AST)
  • alkaline phosphatase (AP) Has a total bilirubin level that is >1.5 times the ULRR at Screening with the exception of suspected or confirmed Gilbert's disease.

    • Pancreatic Disease
  • Secondary causes of diabetes:
  • history of chronic or acute pancreatitis

    • Renal Disease

Significant renal disease at Screening as manifested by:

  • Glomerular filtration rate (GFR) <60mL/min (as calculated by Quest at Visit using the Modification of Diet in Renal Disease (MDRD) equation

    •≥1+ protein on urine dipstick

  • Trace or ≥1+ leukocyte esterase on urine dipstick
  • Trace or ≥1+ blood on urine dipstick
  • Positive nitrite on urine dipstick
  • Recurrent genitourinary tract infections defined as ≥2 episodes of complicated or uncomplicated cystitis or pyelonephritis in the 6 months prior to Screening.

    • Concurrent Disease
  • Has any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests (including blood electrolytes), ECG, including pulmonary, neurological or inflammatory diseases, which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.
  • History of significant co-morbid diseases active in the 6 months prior to Screening (e.g., cholecystitis, acute pancreatitis, gastrointestinal disease, chronic diarrhea, etc.).
  • History of malignancy within the past 5 years other than superficial squamous cell carcinoma (non-invasive on pathology) or basal cell carcinoma (successfully treated with local excision).
  • History of cervical cancer in situ treated definitively at least 6 months prior to Screening.

    • Concurrent Medication

Is currently taking or has taken any of the following medications in the 8 weeks prior to Screening:

  • Digoxin
  • Warfarin and other oral anticoagulants (aspirin and non-steroidal anti-inflammatory drugs are permitted)
  • Bile acid sequestrants
  • Niacin (excluding routine vitamin supplementation)
  • Antiobesity agents (including fat absorption blocking agents)
  • Oral or injectable corticosteroids (inhaled, topical and intranasal corticosteroids are permitted)
  • Loop diuretics
  • Monoamine oxidase inhibitors and tricyclic amines
  • Antiretroviral drugs
  • St John's Wort
  • Oral chromium 9.Breast Feeding 10.Other
  • Current smoker who is unable to abstain from smoking while in the clinic at each visit
  • Has a history of alcohol or substance abuse within the past year at Screening or alcohol or substance abuse during treatment, as determined by the investigator:
  • Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study
  • Has an average weekly intake of alcohol of >21 units or an average daily intake of >3 units (males) or an average weekly intake of >14 units or an average daily intake of >2 units (females). One unit is equivalent to a half pint of beer or 1 measure of spirits or 1 glass of wine
  • Has participated in any study with an investigational or marketed drug in the 3 months prior to Screening.
  • In the opinion of the investigator has a risk of non-compliance with study procedures, or cannot read, understand, or complete study related materials, particularly the informed consent.
  • Known allergy to any of the tablet or capsule excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician, contraindicates participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00495469

Locations
Estonia
GSK Investigational Site
Tallin, Estonia, 13419
GSK Investigational Site
Tallinn, Estonia, 13415
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 129110
GSK Investigational Site
Saint-Peterburgh, Russian Federation, 197022
GSK Investigational Site
St.Petersburg, Russian Federation, 191025
GSK Investigational Site
Tomsk, Russian Federation, 634 050
Ukraine
GSK Investigational Site
Dnipropetrovsk, Ukraine, 49027
GSK Investigational Site
Vinnitsa, Ukraine, 21010
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00495469     History of Changes
Other Study ID Numbers: KG2110375
Study First Received: June 29, 2007
Last Updated: February 21, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Diabetes mellitus HbA1c

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 21, 2014